CLINICAL TRIALS PROFILE FOR RIOMET ER
✉ Email this page to a colleague
All Clinical Trials for RIOMET ER
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00087516 ↗ | Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-06-01 | The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus. |
| NCT00443755 ↗ | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance | Completed | National Center for Research Resources (NCRR) | Phase 2 | 2005-08-01 | The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance. |
| NCT00443755 ↗ | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | 2005-08-01 | The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance. |
| NCT00443755 ↗ | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance | Completed | Takeda Pharmaceuticals North America, Inc. | Phase 2 | 2005-08-01 | The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance. |
| NCT00443755 ↗ | Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance | Completed | Mayo Clinic | Phase 2 | 2005-08-01 | The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance. |
| NCT00682448 ↗ | Metformin for the Prevention of the Metabolic Side-effects of Zyprexa | Completed | Eli Lilly and Company | Phase 4 | 2007-08-01 | We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo. |
| NCT00682448 ↗ | Metformin for the Prevention of the Metabolic Side-effects of Zyprexa | Completed | Rush University Medical Center | Phase 4 | 2007-08-01 | We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RIOMET ER
Condition Name
Clinical Trial Locations for RIOMET ER
Trials by Country
Clinical Trial Progress for RIOMET ER
Clinical Trial Phase
Clinical Trial Sponsors for RIOMET ER
Sponsor Name
